🇺🇸 Fosaprepitant for Injection in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dyspnoea — 2 reports (18.18%)
  2. Blood Pressure Increased — 1 report (9.09%)
  3. Chest Discomfort — 1 report (9.09%)
  4. Dizziness — 1 report (9.09%)
  5. Erythema — 1 report (9.09%)
  6. Flushing — 1 report (9.09%)
  7. Heart Rate Increased — 1 report (9.09%)
  8. Hypertension — 1 report (9.09%)
  9. Off Label Use — 1 report (9.09%)
  10. Product Preparation Issue — 1 report (9.09%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Fosaprepitant for Injection approved in United States?

Fosaprepitant for Injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Fosaprepitant for Injection in United States?

Montefiore Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.